Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be attending and presenting at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. Detailed information about the presentation is below.
乔治亚州诺克罗斯，2024年5月13日（GLOBE NEWSWIRE）——靶向半乳糖凝集素蛋白疗法的领先开发商Galectin Therapeutics Inc.（纳斯达克股票代码：GALT）今天宣布，该公司将出席H.C. Wainwright 2并在会上发表演讲nd 年度生物连接投资者大会。有关该演示文稿的详细信息如下。
H.C. Wainwright 2nd Annual BioConnect Investor Conference
H.C. Wainwright 2nd 年度BioConnect投资者大会
Format: Fireside chat
格式：炉边聊天
Date and time: May 20, 2024 at 4:00 PM ET
日期和时间：美国东部时间 2024 年 5 月 20 日下午 4:00
Location: Nasdaq World Headquarters, New York City
地点：纽约市纳斯达克全球总部
Webcast:
网络直播：
Galectin management team will be available for one-on-one meetings during the conferences. Interested investors should contact their representative at H.C. Wainwright. A Link to access the webcast will be posted, when available, to the Company's website on the Events & Presentation page of the investors section.
Galectin管理团队将在会议期间提供一对一的会议。感兴趣的投资者应联系其在H.C. Wainwright的代表。访问网络直播的链接将在可用时发布到公司网站投资者部分的活动和演示页面上。
About Galectin Therapeutics
关于半乳糖凝集素疗法
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at .
Galectin Therapeutics致力于开发新疗法，以改善慢性肝病和癌症患者的生活。Galectin的主要药物belapectin是一种基于碳水化合物的药物，可抑制半乳糖凝集素-3蛋白，该蛋白直接参与多种炎症、纤维化和恶性疾病，并获得了美国食品药品监督管理局的Fast Track认证。主要开发项目是与代谢功能障碍相关的脂肪性肝炎（MASH，前身为非酒精性脂肪性肝炎，简称NASH）和肝硬化，这是最严重的MASH相关纤维化。肝硬化是最紧迫的医疗需求之一，也是重要的药物开发机会。其他开发计划正在治疗晚期头颈癌和其他恶性肿瘤的联合免疫疗法。这些额外临床项目的进展在很大程度上取决于寻找合适的合作伙伴。Galectin力求利用广泛的科学和开发专业知识以及与外部来源的既定关系，实现具有成本效益和高效的开发。其他信息可在以下网址获得。
Company Contact:
公司联系人：
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
杰克·卡利卡特，首席财务官
(678) 620-3186
ir@galectintherapeutics.com
Investors Relations Contacts:
投资者关系联系人：
Kevin Gardner
kgardner@lifesciadvisors.com
凯文·加德纳
kgardner@lifesciadvisors.com
Chris Calabrese
ccalabrese@lifesciadvisors.com
克里斯·卡拉布雷斯
ccalabrese@lifesciadvisors.com
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics' galectin-3 inhibitor GR-MD-02.
Galectin Therapeutics 及其相关徽标是 Galectin Therapeutics Inc. 的注册商标。Belapectin 是 Galectin Therapeutics 的半乳凝集素-3 抑制剂 GR-MD-02 的美国指定名称。